DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
LGX818
Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate
Novartis Institutes for Biomedical Research and Genomics Institute of the Novartis Research Foundation to treat melanoma with a specific mutation in B-RAF kinase V600E, selective mutant B-RAF kinase inhibitor
LGX818 is currently in Phase Ib/II clinical trials. Patients with colon cancer or melanoma with the BRAF mutation, including patients resistant to other BRAF-targeted drugs, are receiving LGX818 pills alone or as part of drug cocktails to determine whether the drug is safe and efficacious
A phase Ib/II drug structure by Novartis disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat melanoma with a V600E mutation in the B-RAF kinase which it inhibits.[1][2][3]
Several clinical trials of LGX818 , either alone or in combinations with the MEK inhibitorMEK162[4], CDK4 inhibitor LEE011[5] are being run. The initial results are encouraging [6].
- C. Drahl, Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA, 2013, http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/
- http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011023773
- http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011025927
- http://www.cancer.gov/clinicaltrials/search/view?cdrid=728588&version=HealthProfessional&protocolsearchid=11645832
- http://www.cancer.gov/clinicaltrials/search/view?cdrid=745927&version=HealthProfessional&protocolsearchid=11645832
- http://www.novartis.com/downloads/investors/event-calendar/2012/6-bridging-science-and-patients.pdf
New Drug Approvals 
Reblogged this on Srilanka-Chem.
LikeLike
Reblogged this on MED.CHEM in BURMA.
LikeLike
Reblogged this on MEDCHEMEGYPT.
LikeLike
Reblogged this on MedCheminSingapore by Sushma Wang.
LikeLike